• PDF / 169,533 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 56 Downloads / 148 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 5 case reports In a retrospective review of 10 paediatric patients with Hodgkin lymphoma treated between 2015 and 2019, 5 patients (3 boys and 2 girls) aged 12–17 years were described, who developed neutropenia, dyspnoea, neuropathy or hypersensitivity reaction during treatment with brentuximab vedotin. All the patients had a history of Hodgkin lymphoma, for which they were receiving brentuximab vedotin [routes and dosages not stated]. During treatment, the patients developed brentuximab vedotin-related toxicities, which was grade 3 neutropenia (1 patient), mild dyspnoea (1 patient), severe dyspnoea (1 patient), grade 3 motor and sensory neuropathy (1 patient) and grade 3 hypersensitivity reaction (1 patient) [duration of treatment to reaction onset not stated]. For the patient who developed neutropenia the interval between doses was increased. The patient who had mild dyspnoea had completed 16 doses of consolidative brentuximab vedotin. The patient with severe dyspnoea had discontinued the treatment. The patient who developed neuropathy had discontinued brentuximab vedotin at cycle 13. Thereafter, neuropathy had resolved [not all outcomes stated]. Titapiwatanakun R, et al. Toxicities of brentuximab vedotin in children and adolescents with hodgkin lymphoma. Blood 134 (Suppl. 1): no pagination, 13 Nov 2019. Available 803446539 from: URL: http://doi.org/10.1182/blood-2019-122973 [abstract]

0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 18 Jan 2020 No. 1787